Prostate cancer is the most common cancer and the second most common cause of cancer-related death in men in the USA 1 . Despite advances in prostate cancer screening, surgery, hormone-related therapy, and chemotherapy, ~27,000 men still die of metastatic prostate cancer each year in the USA 1 . Of the patients with prostate cancer who receive radical prostatectomy or radiotherapy to treat their primary tumours, ~30% will have biochemical recurrence of their disease based on rising serum PSA levels 2 (Fig. 1) . Approximately 40% of men with biochemical recurrence will develop metastatic disease, and 100% of those patients will die owing to their prostate cancer 2 . Notably, 100% of men who died owing to prostate cancer and who underwent autopsy had prostate cancer bone metastases 3 . Metastases often appear years after primary treatment, indicating that tumour cells must have escaped the primary tumour before therapy (involving invasion and intravasation) and disseminated to distant sites (involving extravasation to distal tissues) [4] [5] [6] . Tumour cell escape, dissemination, and metastasis is a complicated multistep process 7 that requires primary tumour cells to enter the vasculature (intravasation), where they are referred to as circulating tumour cells (CTCs). Most CTCs are unable to withstand the shear stress, immune surveillance, and lack of cell-cell adhesion in the circulation and will die before reaching distant sites. CTCs that are able to exit the circulation (extravasation) and establish residence at a distant site, such as the bone marrow, are called disseminated tumour cells (DTCs). The specific timing of this cellular dissemination process in the natural history of prostate cancer progression before metastatic development is largely unknown but highly intriguing (Fig. 1) . Answering the many unknown questions about the metastatic process, such as why prostate cancer cells predominantly metastasize to bone or how dormant DTCs reawaken to form overt metastatic lesions, could lead to novel therapeutic strategies. Metastatic prostate cancer remains incurable, and current imaging modalities are not sensitive enough to detect individual cancer cells or small colonies of disseminated cells 8 . If CTCs and bone marrow-derived disseminated DTCs (BM-DTCs) could be identified before the formation of overt metastatic lesions, treatments could be aimed at preventing metastasis altogether [9] [10] [11] . Fine needle biopsy sampling is the standard modality for prostate cancer diagnosis and prognosis, but this process is invasive and can cause substantial morbidity Abstract | Despite improvements in early detection and advances in treatment, patients with prostate cancer continue to die from their disease. Minimal residual disease after primary definitive treatment can lead to relapse and distant metastases, and increasing evidence suggests that circulating tumour cells (CTCs) and bone marrow-derived disseminated tumour cells (BM-DTCs) can offer clinically relevant biological insights into prostate cancer dissemination and metastasis. Using epithelial markers to accurately detect CTCs and BM-DTCs is associated with difficulties, and prostate-specific markers are needed for the detection of these cells using rare cell assays. Putative prostate-specific markers have been identified, and an optimized strategy for staining rare cancer cells from liquid biopsies using these markers is required. The ideal prostate-specific marker will be expressed on every CTC or BM-DTC throughout disease progression (giving high sensitivity) and will not be expressed on non-prostate-cancer cells in the sample (giving high specificity). Some markers might not be specific enough to the prostate to be used as individual markers of prostate cancer cells, whereas others could be truly prostatespecific and would make ideal markers for use in rare cell assays. The goal of future studies is to use sensitive and specific prostate markers to consistently and reliably identify rare cancer cells.
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. Of the patients with prostate cancer who receive radical prostatectomy or radiotherapy to treat their primary tumours, ~30% will have biochemical recurrence of their disease based on rising serum PSA levels 2 ( Fig. 1 ). Approximately 40% of men with biochemical recurrence will develop metastatic disease, and 100% of those patients will die owing to their prostate cancer 2 . Notably, 100% of men who died owing to prostate cancer and who underwent autopsy had prostate cancer bone metastases 3 . Metastases often appear years after primary treatment, indicating that tumour cells must have escaped the primary tumour before therapy (involving invasion and intravasation) and disseminated to distant sites (involving extravasation to distal tissues) [4] [5] [6] . Tumour cell escape, dissemination, and metastasis is a complicated multistep process 7 that requires primary tumour cells to enter the vasculature (intravasation), where they are referred to as circulating tumour cells (CTCs). Most CTCs are unable to withstand the shear stress, immune surveillance, and lack of cell-cell adhesion in the circulation and will die before reaching distant sites. CTCs that are able to exit the circulation (extravasation) and establish residence at a distant site, such as the bone marrow, are called disseminated tumour cells (DTCs). The specific timing of this cellular dissemination process in the natural history of prostate cancer progression before metastatic development is largely unknown but highly intriguing (Fig. 1) . Answering the many unknown questions about the metastatic process, such as why prostate cancer cells predominantly metastasize to bone or how dormant DTCs reawaken to form overt metastatic lesions, could lead to novel therapeutic strategies. Metastatic prostate cancer remains incurable, and current imaging modalities are not sensitive enough to detect individual cancer cells or small colonies of disseminated cells 8 . If CTCs and bone marrow-derived disseminated DTCs (BM-DTCs) could be identified before the formation of overt metastatic lesions, treatments could be aimed at preventing metastasis altogether [9] [10] [11] . Fine needle biopsy sampling is the standard modality for prostate cancer diagnosis and prognosis, but this process is invasive and can cause substantial morbidity 12 .
Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies Emma E. van 2, 3 , Jean J. de la Rosette 4 Thus, investigating the clinical utility of minimally invasive liquid biopsies from blood or bone marrow that use CTCs and BM-DTCs as biomarkers of disease is appealing [12] [13] [14] . Accurate detection of these cells will also enable their biological characterization, so that therapies can be precisely targeted to the mechanisms leading to recurrence. Liquid biopsies can also provide clinically relevant information in the form of cell-free circulating tumour DNA (ctDNA) and exosomes, both of which can also be present in urine [15] [16] [17] (Fig. 2) . Liquid biopsies can provide a real-time noninvasive snapshot of the total tumour burden that a patient has and can provide important complementary information on therapeutic targets and mechanisms of drug resistance 18 . The number of CTCs found in patients with castration-resistant prostate cancer (CRPC) can predict overall survival. Patients with ≤5 CTCs per 7.5 ml of blood survived 10.2 months longer than patients with >5 CTCs per 7.5 ml of blood, identified using EpCAM-based purification methods 19 . Other studies have correlated the number of CTCs in samples from patients with metastatic prostate cancer with therapeutic response and survival 19 . Most of these studies have been done in the metastatic setting, but some early data indicate similar conclusions in the premetastatic setting [20] [21] [22] [23] [24] [25] . Overall, information from CTCs from blood draws is extremely clinically relevant and will continue to be so. Clinical correlations and outcomes have not been as rigorously assessed for BM-DTCs, as bone marrow is more difficult to obtain and identifying BM-DTCs is more difficult than CTCs, owing to decreased marker specificity. CTCs will probably have a more important role in providing clinically relevant data in real-time, but BM-DTCs could be a more important cell population for metastasis research, as they have successfully migrated from the primary tumour to a distal site. We propose that BM-DTC data will provide much needed information about timing of dissemination, as well as the genetic and epigenetic characteristics of a successfully disseminated and proliferating cancer cell. Thus, the ultimate goal is to determine prostate-specific markers that sensitively and specifically identify BM-DTCs for downstream analysis.
Detecting rare prostate cancer cells Understanding the characteristics and clinical application of CTCs and BM-DTCs after they are reliably detected is important. The two most commonly used methods for CTC detection are reverse transcription PCR (RT-PCR) and fluorescence-based immunostaining (referred to as immunofluorescence). Fluorescence in-situ hybridization (FISH) can be used as a tool similar to immunofluorescence and RT-PCR to identify CTCs via RNA expression, thereby helping to define the differential gene expression patterns within these cells 26 . This method is not commonly used owing to the technical challenge of combining FISH and immunofluorescence. Each of these methods has its own advantages and limitations (Table 1) , but immunofluorescence has certain advantages that enable further biological characterization of functional activity at the time of detection. RT-PCR is more sensitive, and the assay itself is less technically challenging, whereas immunofluorescence enables the differentiation of protein expression on different cell populations and permits further downstream analysis via single-cell picking. Many different commercially available assays exist for the detection of CTCs (very few exist for BM-DTCs), and most rely on positive selection of cancer cells or negative selection of leukocytes, but selection-free methods also exist [27] [28] [29] . Most methods also involve the separation of red blood cells from white blood cells (WBCs) and cancer cells, which is commonly achieved using microfluidics chips, red blood cell lysis buffers, and/or centrifugation-based separation [28] [29] [30] [31] . The type of detection methodology changes the resulting cell population and molecular composition that is analysed, as certain cell types can be enriched or lost, based on the experimental conditions. For instance, analysing wholeblood RNA for a specific marker without including a selection step will not yield meaningful results about the specificity of that marker to cancer cells. Many studies have used selection methods (usually via epithelial selection based on EpCam expression or size-based selection using a microchip) to detect CTCs from blood using RT-PCR, multiplex PCR, or digital droplet PCR [32] [33] [34] [35] [36] [37] [38] [39] . These studies show that RT-PCR is extremely sensitive for CTCs, but this method has not been successful for sensitively identifying BM-DTCs.
Current standard markers used for CTC detection via immunofluoresence include a nuclear marker (usually 4ʹ,6 diamidino-2 phenylindole (DAPI)), a marker for WBCs (usually CD45), and one or more epithelial markers (usually EpCAM and/or pancytokeratin) 19, 40 . A major limitation of relying on epithelial markers for CTC identification is that these markers are not always highly expressed on cancer cells, and have also been shown to be expressed on cells of haematopoietic lineage [41] [42] [43] [44] [45] [46] . Furthermore, CTCs are thought to lose their epithelial phenotype after undergoing epithelial-mesenchymal transition (EMT) to escape the primary tumour and, therefore, they might lose EpCAM and/or cytokeratin expression [47] [48] [49] [50] [51] [52] . EpCAM-based detection methods have been the most commonly used to identify CTCs, but how frequently this loss of epithelial characteristics occurs is not known, thereby potentially limiting their
Key points
• liquid biopsies, particularly from bone marrow, might enable the detection of recurrent disease before overt lethal metastasis develops.
• Prostate cancer cells in liquid biopsies, particularly bone marrow, are rare and extremely difficult to identify accurately.
• Prostate-specific markers analysed using rare cell immunofluorescence assays might help identify rare prostate cancer cells from liquid biopsies.
• expression of putative prostate-specific markers is not always constrained to prostate cells. The sensitivity and specificity of assays of expression of candidate markers for rare cells must be ascertained on an individual basis.
• Immune cells in the blood and bone marrow are a considerable source of nonspecific staining, so measures must be taken to reduce this background staining.
• Combinatorial staining of multiple prostate-specific markers will increase accuracy for identifying rare prostate cancer cells in liquid biopsies, and improve understanding of the role of important cells in prostate cancer metastasis and aid clinical application.
use. In addition, the blood, and particularly the bone marrow, contains a vast heterogeneity of cells, many of which are stem cells or other cells that can epigenetically alter their phenotype. This heterogeneity can lead to false-positive immunostaining, in which the detection marker is no longer specific for prostate cells. Once CTCs are isolated, further characterization can be performed using different functional assays, such as EPISPOT, which detects specific proteins during in vitro culture of CTCs 53 . Another example of CTCs being used in preclinical models is the xenograft model, in which cancer cells from cell lines or patient-derived CTCs are injected into immune-compromised mice, after which metastases will develop 54, 55 . These xenograft models can be used for preclinical drug evaluation, biomarker identification, and other biological studies, but this method has not been successfully used in prostate cancer research. Understanding gained using these techniques can give important information that might result in individualized treatment of cancer.
We posit that the use of prostate-specific markers to identify prostate CTCs and BM-DTCs will enable more sensitive and specific detection of these rare cancer cells. To date, the identification of these markers of rare tumour cells has been challenging, as some reported prostate-specific markers are not very sensitive (not expressed in all prostate cancer cells) or specific (also expressed by other cells in the blood or bone marrow) (Supplementary Table 1 ). Many studies on these markers have only assessed expression of protein at the tissue level (using immunohistochemistry (IHC) on formalinfixed, paraffin-embedded tissue) or RNA in whole blood (using RT-PCR), neither of which represents true sensitivity or specificity at the rare cell level. Thus, each of these markers should be assessed using rare cell assays in blood and bone marrow samples before any conclusion can be made as to their utility in liquid biopsies. Also, dedifferentiation and loss of prostate-specific markers can occur in a considerable proportion of poorly differentiated prostatic adenocarcinomas 49, 56, 57 . Thus, finding highly sensitive and specific prostate markers that are expressed during all stages of a patient's disease, are expressed on every tumour cell, and are not expressed on any blood or bone marrow cells is imperative. In this Review, we discuss our current knowledge of the putative prostatic-lineage markers and highlight their advantages and limitations in the detection of CTCs and BM-DTCs (Table 2) is produced by secretory epithelial cells in the prostate 58 and is an androgen-regulated serine protease expressed in both benign and malignant prostatic tissue. PSA is one of the oldest prostatic markers used in IHC to confirm that a metastatic carcinoma is prostatic in origin 59 . PSA has been widely shown to have a high specificity for prostate cancer, but its expression also tends to decrease with cancer progression 60 . PSA expression can be absent in ~5% of patients with high-grade prostate cancer and distant metastases, as well as in ~10% of lymph node metastases 49, [60] [61] [62] [63] . The staining pattern for PSA is cytoplasmic, which can be an issue in IHC because diffuse cytoplasmic staining can generate false positives during analysis 64 . PSA expression has been reported in a variety of nonprostatic tissues and tumours, including breast and lung carcinomas 61, [65] [66] [67] [68] [69] , but others have reported high sensitivity and specificity of PSA for prostate cancer using monoclonal and polyclonal anti-PSA antibodies 70 . PSA expression in blood from patients with prostate cancer correlates positively with prostate cancer occurrence at the RNA level using RT-PCR, but no selection protocol was used to ascertain which cells expressed PSA 34, 71 . Overall, PSA is a promising marker for rare cell assays, as it seems to be sensitive for most prostate cancer cells and expression has not been reported in blood or bone marrow cells (unlike androgen receptor (AR) expression), although expression patterns must be tested in rare cell assays. PSA specificity coupled with evidence that PSA can be controlled in an AR-independent manner 72 means that PSA could potentially be a more promising rare cell marker than AR. PSA is also a widely used biomarker of primary prostate tumour growth and biochemical recurrence following radical prostatectomy or radiotherapy 73 . The full utility of PSA as a sensitive and specific rare cell marker in blood and bone marrow has yet to be ascertained in patients with prostate cancer and people without cancer.
PSA belongs to the kallikrein serine protease family, which has 15 members. Besides PSA, two other kallikrein family members, KLK2 and KLK4 (also known as prostase and KLK-L1), also seem to be prostate specific, ascertained by performing IHC on multiple non-prostate tissues [74] [75] [76] [77] [78] [79] [80] [81] . Less is known about the clinical utility of these markers, but both have been observed in tissue and serum from patients with prostate cancer [74] [75] [76] [77] [78] [79] [80] [81] . Both KLK2 and KLK4 seem to have a proteolytic function in activating PSA from its precursor pro-PSA form. These kallikreins should be assessed in rare cell assays in addition to PSA.
Androgen receptor. The AR is the most widely studied protein related to prostate development and prostate cancer. AR is a transcription cofactor that affects the development and growth of male sex organs, including the prostate 82 . Androgen-mediated nuclear localization and activation of AR is required for the development and growth of the prostate gland [83] [84] [85] [86] , and deprivation of androgens inhibits proper ductal development of the gland 87 . These phenotypes can be seen during embryonic development, in which fetal testicular secretion of androgens promotes prostate development 85 . Structural maintenance and reproductive function of the adult prostate also requires androgens and AR activity 88 . Binding of dihydrotestosterone to AR causes translocation to the nucleus and binding to androgen response elements in genomic DNA to initiate 89, 90 or downregulate transcription of target genes 91, 92 . AR also has nontranscription-related functions, such as activation of SRC kinase activity, thereby enhancing cellular invasion, but these functions are not well understood and have only been reported in prostate cancer tissue 93 . Expression of many other prostate-specific genes is transcriptionally regulated by AR. AR has critical roles in prostate cancer owing to its crucial functions in the development, growth, and maintenance of the prostate. Some groups have reported tumorigenic properties of AR in mouse models of prostate cancer 94, 95 . However, mice lacking AR specifically in the prostate had increased cellular proliferation, indicating that the role of AR in cancer initiation is still not fully understood 96 . Interestingly, prostate cancer is one of the most prevalent cancers in men, but almost no cancers of the seminal vesicle or bulbourethral gland occur, both of which express AR 97 . AR is strongly expressed in most prostate cancer tumours, and prostate cancer maintenance seems to depend on AR signalling [98] [99] [100] [101] . Androgen deprivation therapy (ADT) and AR targeting therapies result in substantial survival benefits in patients with advanced prostate cancer and are widely used in the clinical setting [102] [103] [104] . AR expression can be lost in some prostate cancer tumours, particularly those with neuroendocrine or small-cell prostate cancer pathology, so for these specific cancers, AR is not a good marker [105] [106] [107] [108] . The AR splice variants are of www.nature.com/nrurol great interest and have potential utility in rare cell assays. Expression of the AR-V7 variant has been shown to increase in CRPC 109 . Moreover, expression of the fulllength version of AR in prostate cancer CTCs generally indicates a positive response to ADT, whereas expression of the AR-V7 variant generally indicates a negative response to ADT, in which case chemotherapy would be prescribed over ADT 23, 49, 110, 111 , and this predictive ability has led to the use of AR-V7 expression levels in CTCs in guiding therapeutic strategy 21 . However, the use of AR solely as a CTC and/or BM-DTC marker for rare cell assays has specificity issues because it is expressed on bone marrow cells and platelets, as well as in other tissues [112] [113] [114] [115] (Supplementary Table 1 ). We believe that AR is not specific enough for prostate tumour cells to be used as an individual marker for rare prostate cancer cells but has potential as an adjuvant marker for clinical management. Furthermore, because AR is expressed in certain blood and bone marrow cells and AR regulates the expression of many other putative prostate-specific markers [109] [110] [111] [112] , each of these potential markers must be rigorously assessed for its expression in blood and bone marrow to determine specificity for rare prostate cancer cells. The splice variant AR-V7 might be more specific to prostate cells than the parental AR, but this has not yet been assessed. A non-androgen-regulated, prostatespecific gene would be an ideal marker in prostate CTC and BM-DTC detection assays, but such markers are seemingly rare.
Prostate-specific membrane antigen. Prostate-specific membrane antigen (PSMA; also known as folate hydrolase 1 (FOLH1)) is a membrane-bound glycoprotein with high specificity for both benign and malignant prostatic tissue. In contrast to other androgen-regulated prostate genes, PSMA is suppressed by androgens in an AR-dependent manner 116 . PSMA is currently being explored extensively as a promising target for molecular imaging and therapeutics in prostate and renal cancers 117 . For prostate cancer, PSMA might be useful in the setting of biochemically recurrent disease, in which PSMA-targeted radiotracers seem to be superior to conventional imaging for detection of metastatic prostate cancer 8, 118, 119 . PSMA is highly upregulated in high-grade tumours and corresponding metastases, in contrast to PSA 120 . Benign prostate epithelium often has a low level of diffuse cytoplasmic PSMA staining, whereas highgrade and metastatic tissues mostly have a very intense cytoplasmic and focal membrane staining 63, 120 . PSMA was originally thought to be strictly expressed in prostatic tissue, but, unfortunately, PSMA is now known to be widely expressed in a variety of nonprostatic solid tumours, including urothelial, renal, gastrointestinal, and breast carcinomas, the vasculature, bone in diseases such as Paget disease, and healing bone fractures [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] (Supplementary Table 1 ). PSMA expression in nonprostatic cancer cells is mostly restricted to the cytoplasm 63 . Furthermore, one study reported the detection of the PSMA protein in an exceptional variety of healthy tissues, including the urinary bladder and proximal tubules of the kidney 123 . mRNA expression of PSMA in normal human male and female bone marrow has been demonstrated, but no protein expression was observed 115 . PSMA expression in blood from patients with or without prostate cancer was ascertained in a selection-free manner via RT-PCR of whole-blood RNA, and its sensitivity and specificity were reported as 59% and 47%, respectively; however, which cells expressed the marker could not be ascertained, owing to the lack of selection 132 . PSMA is a promising marker for overt prostate tumour detection, but the application of PSMA as a marker for rare prostate cancer cells needs further assessment, as its true specificity is still in question.
Prostate stem cell antigen. Prostate stem cell antigen (PSCA) is an androgen-regulated glycosylphosphatidylinositol-anchored, membrane-bound glycoprotein, originally identified as a prostate-specific, tumour-promoting antigen 133, 134 . Expression of PSCA is restricted to the basal layer of the prostate 133 . Approximately 88-94% of primary prostate cancer specimens express PSCA 133, 135 , and in one study 100% (9/9) of bone metastatic lesions were positive for PSCA expression 135 . In another study, PSCA protein expression was observed in 87.2% (41/47) of bone meta stases 136 . PSCA might be a useful marker for prostate cancer diagnosis [136] [137] [138] , as one study reported PSCA mRNA expression in the peripheral blood of 71% of samples NATuRe RevIews | URoLogy from patients with prostate cancer, 13% of samples from men with benign prostatic hyperplasia, and 0% of men without prostatic disease 139 . A similar study reported PSCA sensitivity of 40% in patients with gastrointestinal tumours, which would indicate a lack of prostate specificity 140 ; however, because no selection process was undertaken in these studies, whole-blood RNA was assessed, so whether the PSCA-positive cells were actually prostate cells or another type of cell is unclear. This drawback of RT-PCR is considerable compared with immunofluorescence assays. At least two reports using PCR and IHC show absence of PSCA expression in nonprostatic tissue 133, 135 , but others have found expression in the normal epithelium of various tissues, including the urinary bladder, kidney, and intestine 115, 135, [141] [142] [143] (Supplementary Table 1 ). PSCA is also overexpressed in various cancers, including urothelial, kidney, and lung [144] [145] [146] [147] [148] . In some cancers, PSCA is downregulated, indicating it might also have a tumour suppressive role, depending on the tissue 141, 143, [149] [150] [151] . Overall, data suggest that PSCA expression is not actually specific to the prostate, which means it is not a desirable marker for rare cell assays on its own. However, its expression in the basal cell compartment of the prostate indicates that it could potentially be used for certain subsets of prostate cancer that are of basal cell origin.
α-Methylacyl-CoA racemase. α-Methylacyl-CoA racemase (AMACR; also known as P504S) is a peroxisomal and mitochondrial enzyme that is involved in bile acid biosynthesis and β-oxidation of branched-chain fatty acids, and it is not androgen-regulated 152, 153 . AMACR expression is observed in a granular pattern in the cytoplasm. AMACR is expressed in other normal tissues, including bone marrow cells, as well as normal prostatic tissue 115 (Supplementary Table 1 ). AMACR is also overexpressed in almost every type of carcinoma assessed, including over 95% of prostate cancers 115, 154, 155 . Thus, AMACR is not useful in distinguishing prostate cancer from other malignancies; however, it is still commonly used as a diagnostic biomarker for prostate cancer, as expression is stronger in malignant tissue than nonmalignant tissue, and it is often used in IHC assays in combination with a negative marker for prostate cancer such as the basal cell marker p63 (reFs [156] [157] [158] ). In an RNAbased study using patient blood, AMACR expression was found in 73% of patients with prostate cancer, as well as 55% of patients without prostate cancer, indicating poor sensitivity and specificity, although no selection process was undertaken so assessing which cells were expressing the marker is not possible 159 . AMACR can be detected in both prostate adenocarcinoma at ~80% sensitivity, as well as rare prostate cancers, such as pseudo hyperplastic, atrophic, ductal, and mucinous prostate cancers 158, 160 . AMACR is also overexpressed in noncancerous prostate diseases, such as adenosis, postatrophic hyperplasia, partial atrophy, and prostatic intraepithelial neoplasia 161 . AMACR RNA is expressed in the bone marrow 115 , it cannot, therefore, be used for BM-DTC detection in PCR assays. Nevertheless, more work needs to be done to determine its sensitivity and specificity in rare cell assays. 
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Prostate-specific acid phosphatase. Prostate-specific acid phosphatase (PSAP; also known as prostatic acid phosphatase (PAP) and prosaposin), is a glycoprotein that hydrolyses esters under acidic conditions to yield inorganic phosphates, and it is one of the major proteins that is secreted by the prostate 162, 163 . PSAP is an androgen-regulated protein that was first discovered in 1938 by Gutman and colleagues 164 , who showed that the level of PSAP was increased in the blood of patients with localized prostate cancer and was even more highly expressed in those with metastatic disease relative to healthy individuals. Thus, PSAP became the first serum tumour marker for biochemical testing to diagnose and monitor progression of prostate cancer. Subsequently, PSA was found to be a more sensitive and specific biomarker and replaced PSAP in these assays. One study including 460 patients with localized prostate cancer showed only 0.9% of men were PSAP-positive and PSA-negative, indicating that PSAP detection would not capture additional cancer cells that would not already be detected by PSA 165 . PSAP is still occasionally used for the evaluation of prostate cancer tissue by IHC, in which it shows granular staining pattern in the cytoplasm. PSAP is expressed at moderateto-high levels in normal prostate tissue and is strongly expressed in >95% of malignant prostatic tissue [166] [167] [168] . These studies are tissue-based and not cell-based, but they do suggest that PSAP might be a sensitive marker for prostate cancer in general. However, one study showed that PSAP was expressed in only 84% and 77% of lymph node and distal metastases, respectively, suggesting that expression might be lost in a clonal manner during metastasis 63 . PSAP is also expressed in a variety of other cancers, including melanoma, lymphoma, cancer of the testis, and urothelial cancer 115 (Supplementary Table 1 ). Several studies have reported expression of PSAP protein in nonmalignant nonprostatic tissues, including granulocytes 115, 166, [168] [169] [170] [171] [172] . Importantly, PSAP protein and mRNA have been detected in normal bone marrow tissues from women and men, indicating poor specificity for BM-DTC detection 115 . Despite its high expression in most prostate carcinomas, the distribution of PSAP expression in other healthy tissues, particularly immune cells and other bone marrow cells 115 , indicates that PSAP is not as prostate-specific as was initially suggested and might not be specific enough to be used alone as a detection marker for CTCs or BM-DTCs.
TMPRSS2-ERG.
TMPRSS2 is androgen-regulated and is located close to ERG on chromosome 21. In ~50% of patients with prostate cancer a gene rearrangement occurs between TMPRSS2 and ERG, which produces the androgen-regulated overexpression of fusion protein transmembrane protease, serine 2 (TMPRSS2)-erythroblastosis virus E26 transformation specific related gene (ERG), in which ERG is the driving oncogene 173 . The TMPRSS2-ERG fusion is typically assessed using FISH, and is nearly 100% specific for prostate tissue (Supplementary Table 1 ). ERG expression assessed using IHC can also be used as a surrogate marker for expression of the fusion gene 174 , and ERG staining has been associated with worse prognosis in patients with prostate cancer 175 . Even before the discovery of the TMPRSS2-ERG gene fusion, ERG overexpression in prostate cancer had been reported, indicating it might have a role in prostate tumorigenesis and, therefore, might be a biomarker of prostate cancer 176 . TMPRSS2-ERG has utility as a biomarker in urine tests (similar to prostate cancer antigen 3 (PCA3)) with 37% sensitivity and 93% specificity 177 . When TMPRSS2-ERG and PCA3 detection in urine samples was combined, sensitivity increased to 73%, which still falls short of the sensitivity required for a rare cell assay. However, both of these markers should continue to be studied as markers of rare cells (owing to their high specificity for prostate cells) in combination with other markers. The biggest advantage of using TMPRSS2-ERG to detect prostate cells is that it is specific to prostate cancer cells and has not been found in nonmalignant prostate tissue. Most of the other candidate prostate-specific markers have been detected in benign tissue, making it difficult to differentiate cancerous from benign tissue. In rare cell assays, only cancer cells are likely to be present in blood or bone marrow, but this assumption has not been definitively proven. Possibly, noncancer cells could slough into the blood and be identified as cancer cells based on expression of prostate-specific markers. In patients known to have TMPRSS2-ERG expression in their primary tumour, including TMPRSS2-ERG as an additional marker for CTC and BM-DTC detection would eliminate doubt about the origin of the rare cells in question. Notably, other gene fusions exist in prostate cancer, including a SLC45A3-ERG fusion 178 , TMPRSS2 fusion with other ETS family genes such as TMPRSS2-ETV4 (reF.
179 ), as well as many other fusions that have not been assessed for their sensitivity but could be useful in identifying cancer cells in a multiplex FISH staining strategy, which would more accurately detect gene fusions 180 .
Prostate cancer antigen 3. PCA3 (which was initially known as differential display clone 3 (DD3)), is an androgen-regulated long non-coding RNA (lncRNA) that was discovered in 1999 (reFs 181, 182 ). PCA3 downregulates expression of the tumour suppressor PRUNE2, thereby promoting tumour progression 183, 184 . PCA3 is overexpressed in around 95% of prostate cancers and is thought to be prostate-specific, as it was not detected in 18 other nonmalignant tissues in a major study (although blood and bone marrow were not assessed) 181 (Supplementary Table 1 ). PCA3 cannot be detected by IHC or immunofluorescence because it is a lncRNA, and its detection is limited to RT-PCR or RNA in situ hybridization (ISH) assays 31, 185 . PCA3 is currently being tested as a urinary biomarker for prostate cancer, although its sensitivity is limited, even when combined with other urinary biomarkers, such as TMPRSS2-ERG fusion 177, 186, 187 . Overall, PCA3 has some promise as a marker of rare prostate cancer cells, but because the combination of immunofluorescence with RNA ISH or RT-PCR is technically challenging, we are less enthusiastic about the practicality of this marker for rare cell assays than other biomarkers.
Homeobox protein NKX3.1. NKX3.1 is a homeoboxcontaining transcription factor that is androgenregulated and has relatively high specificity for prostate tissue, although its expression can be regulated independently of AR, similar to PSA. NKX3.1 is often used as a marker of prostatic origin in metastatic tumours using IHC 188 . NKX3.1 is primarily detected in secretory prostatic epithelial cells, and its staining pattern is mainly nuclear, although it can also be detected in the cytoplasm 189 . This protein was one of the earliest discovered markers of prostate development 190 and is a putative tumour suppressor in prostate cancer, as it functions to inhibit prostate cell growth and proliferation in a context-dependent manner and one allele is frequently deleted in patients with prostate cancer 190 . NKX3.1 expression has been reported to be high in primary prostate tumours, but low in high-grade tumours and absent in metastatic prostate cancer 191, 192 . However, Gurel and colleagues 188 assessed the performance of NKX3.1 as a marker of hormone-naive metastatic prostate cancer and found that the sensitivity of NKX3.1 expression was 98.6%, as 68 of 69 samples were positive for this marker. The same study showed the specificity of NKX3.1 was 99.7%, as only 1 of 349 nonprostatic tumours was positive. This discrepancy with previous studies is most likely explained by the use of different antibodies 191, 192 . NKX3.1 has been observed in rare invasive lobular breast carcinomas and in benign testis tissue 190, 193, 194 (Supplementary Table 1 ). Uhlén and coworkers 115 detected NKX3.1 expression in a plethora of nonmalignant tissues, including the salivary glands, kidney, testis, and, importantly, the bone marrow, but did not assess protein expression. Altogether, these data suggest that NKX3.1 is relatively sensitive for prostate cancer cells, but potentially not specific enough to differentiate prostate cancer cells from bone marrow cells, although this specificity has yet to be tested at the protein level.
Homeobox B13. Homeobox B13 (HOXB13) is a transcription factor that is involved in prostate development and its expression is androgen independent 195, 196 . HOXB13 might physically interact with AR in the nucleus of prostate cells, potentially in an inhibitory manner 197, 198 . HOXB13 is expressed in nonmalignant prostatic tissue 199 , and overexpressed in prostate cancer 198, 200 , and is used to identify metastatic prostate tissue 201 . The HOXB13 Gly84Glu variant mutation is associated with significantly increased risk of hereditary prostate cancer (P = 8.5 × 10 −7 ) 202 . The fact that truncating mutations in HOXB13 are not reported and the recurrent nature of the Gly84Glu change suggest a carcinogenic mechanism that is most likely of an oncogenic nature (gain of function) and not tumour-suppressive in nature (loss of function). The staining pattern of HOXB13 is primarily nuclear, but it can also be detected in the cytoplasm. Weak-to-moderate cytoplasmic staining has been observed in some nonprostatic cancers, such as in liver and lung cancers 115 (Supplementary Table 1 ). Furthermore, Uhlén and colleagues 115 reported low expression of HOXB13 in patients with lymphoma. A 2016 study by Barresi and colleagues 203 compared the diagnostic value of HOXB13 with PSA protein expression in tissue samples from prostate and urothelial carcinoma to determine if it was of prostatic origin. HOXB13 immunostaining was strong in >75% of the neoplastic cells in 100% (15/15) of the prostatic metastases, and weak staining was found in <25% of the neoplastic cells in 17% (2/12) of urothelial carcinoma metastases. The sensitivity and specificity of HOXB13 for metastatic prostate cancer were 100% and 94%, respectively. In comparison, the sensitivity and specificity of PSA for these metastatic prostate cancer tissues were 53% and 100%, respectively 203 . This result indicates that HOXB13 is, overall, a more accurate biomarker than PSA. Two studies by Varinot and co-workers 199, 201 also assessed HOXB13 sensitivity via IHC and reported that HOXB13 was 89% sensitive and 100% specific in primary prostate tumours 199 , 93% sensitive in lymph node metastases, but only 33% sensitive in bone metastases (although this observation could have been caused by decalcification of the bone tissue) 201 . Another group showed that HOXB13 expression was present in 52% of 10,216 tumour samples from patients with prostate cancer, and that stronger staining was associated with prostate cancer cells than nonmalignant prostate cells, indicating that it would be a useful marker for prostate cancer cells 198 . Interestingly, HOXB13-AR interaction resulted in a reduction in PSA expression, indicating that HOXB13 and PSA could be used together in rare cell immunofluoresence assays to boost sensitivity for all prostate cancer cells -those that express PSA and those that express HOXB13. Overall, these data suggest that HOXB13 is a promising candidate marker for the detection of prostate CTCs and BM-DTCs owing to its specificity and androgen-independence in tissue-based assays, but work needs to be done in rare cell assays to fully ascertain its utility.
PSP94.
Prostate secretory protein of 94 amino acids (PSP94; gene name MSMB) was one of the first three secretory proteins in the prostate to be identified, in addition to PSA and PSAP 204 . PSP94 was originally identified as β-microseminoprotein (MSMB) 205 , or β-inhibin 206 , and is an androgen-regulated, immunoglobulin-binding factor that is secreted into seminal plasma [207] [208] [209] [210] . The specific function of PSP94 is still uncertain, but it possibly increases sperm quality, protects from female immune surveillance 211 , and acts as a fungicidal agent in sperm 212 . PSP94 protein has been found in numerous additional secretions, including mucous gland secretions 213 and its expression has also been detected in tonsil, skin, bronchus, stomach, testis, and seminal vesicle tissue 115 (Supplementary Table 1 ). Levels of PSP94 expression in cancer are somewhat unclear: overexpression of PSP94 has been observed in ovarian cancer, suggesting a tumour-promoting function 214 , whereas several studies have shown that it acts as a tumour suppressor in prostate cancer [215] [216] [217] [218] [219] . One study in prostate cancer tissue showed that PSP94 expression was inversely correlated with Gleason score, but its expression persisted after hormone therapy, whereas PSA expression decreased, indicating that PSP94 expression can be upregulated in the absence of androgens 220 . Support for the putative www.nature.com/nrurol role of PSP94 as a tumour suppressor comes from the observed association of the loss of function of variant MSMB alleles with increasing prostate cancer risk 221, 222 , as well as its antifungal and anti-inflammatory properties 222 EZH2 behaves as an oncogene in prostate cancer and has been shown to target and silence PSP94 (reF.
223
).
Finally, a synthetic peptide corresponding to amino acids 31-45 of PSP94 has been shown to decrease vascular endothelial growth factor expression in endothelial cells, indicating that PSP94 might have antiangiogenic effects 224 . Overall, PSP94 is not likely to be a suitable candidate for CTC and BM-DTC detection owing to its varied expression throughout prostate cancer progression.
Prostein. Prostein (also known as p501s and solute carrier family 45 member 3 (SLC45A3)) is one of the newest prostate-specific markers to have been discovered, having been identified via a genome-based approach in 2001 (reF.
225
). Prostein is an androgen-regulated type IIIa transmembrane protein located in the Golgi apparatus with functions related to macromolecule transport 226 . Prostein is expressed in nonmalignant prostate tissue as well as prostate cancer tissue 63, 227 , even when PSA expression is negative 226, 228 . The staining pattern of prostein is uniquely granular, which helps to distinguish it from other markers and increases confidence of true staining (Fig. 3) . Prostein has been used to differentiate prostate cancer (prostein-positive, p63-negative) from urothelial cancers (prostein-negative, p63-positive) using IHC 57 . Along with HOXB13, prostein is one of the most prostate-restricted proteins in tissue-based assays, although expression has also been observed in lung and bladder cancer 229 (Supplementary Table 1 ). To date, prostein expression has been analysed in hundreds of different nonmalignant nonprostatic tissues, but none of these tissues expressed this marker, indicating its high specificity 115, 227 . One study compared tissue expression at the protein level of prostein with expression of PSA, PSAP, PSMA, AR, and ERG in primary prostate cancer and metastatic tumours, and found that prostein sensitivity was decreased in metastatic tumours relative to primary tumours, although it was still expressed in 89% of tumours 63 . Furthermore, when PSA expression was absent in tumours, prostein and AR were present, indicating that more than one prostate-specific marker should be used to increase sensitivity when using IHC and certainly in rare cell assays. Taken together, we believe that prostein is a promising marker for use in immunofluorescence-based rare prostate cancer cell assays, although its utility has not been directly tested.
Mouse prostate markers
Mice are extensively used as in vivo models of prostate cancer metastasis, and rare cell assays have been developed for xenograft, syngeneic, and transgenic mouse models 31 . Xenograft models use human cancer cells, necessitating a different set of markers for CTC and BM-DTC analysis. However, the similarities and differences between mouse and human prostates at the anatomical and cellular marker expression levels must be considered when using mouse models that develop murine prostate cancer (syngeneic models or genetically engineered mouse models (GEMMs)). The mouse prostate gland is histologically quite similar to the human prostate gland, but considerable differences in anatomy and molecular biology exist (Fig. 4) . The human prostate surrounds the urethra at the base of the bladder and is separated into zones for grading and staging purposes, but anatomical zonation is not grossly apparent. The mouse prostate is composed of several lobes: the anterior lobe, which is immediately next to the seminal vesicle; and the dorsolateral and ventral lobes, which are anatomically similar to those of the human prostate and are at the base of the prostate 230, 231 . In mice and humans, all prostate glandular secretions go into the urethra and make up a substantial portion of the ejaculate. Another considerable difference between the human and mouse prostate is the ratio of luminal to basal cells. In humans the ratio is approximately 1:1, and in mice the ratio is closer to 3:1 (reF.
232
In terms of gene expression, mice do not express PSA, KLK2, or PCA3 (Table 3) . Of the kallikreins, only KLK4 has an orthologue in mice 233 . Mice express a PSCA orthologue (Table 3) , which is 70% similar to human PSCA 133 . PSP94, PSMA, and PSAP are expressed in mice and are specific to the mouse prostate with similar functions to in humans [234] [235] [236] . Mice also express Hoxb13 independent of androgen, and this gene has been used to create a GEMM of prostate cancer 237, 238 . NKX3.1 is another marker present in mice and its role in prostate development and tumorigenesis has been studied extensively in mouse models [239] [240] [241] . Mice also express an AMACR orthologue, although our understanding of its role in mouse prostate biology is limited 242 . Whether prostein is expressed in the mouse prostate at the protein level is unclear, although RNA ISH has shown that Slc45a3 is expressed throughout developing tissue in mouse embryos 243 . Mice express both TMPRSS2 and ERG, although with no prostate specificity, and the TMPRSS2-ERG fusion does not occur in mice because they never develop de novo prostate cancer 244 . Mice also express AR; in fact, many androgen signalling paradigms have been discovered by studying mouse or rat AR. However, an important consideration is that AR activity in mice might differ from humans owing to the amount of testosterone in either species at any given time -proportionally, a hormonally intact male mouse has approximately as much circulating testosterone as an androgen-ablated man 88, 245 . Perhaps the best way to use mice as an in vivo model for rare cell studies is to inject human or mouse cancer cells that are labelled with a highly abundant marker (such as a highly expressed protein or a synthetic fluor escent marker) into mice, harvest blood and/or bone marrow at specific time points, and then use the genetic marker for CTC and/or BM-DTC detection 31 . Conducting rare cancer cell research is inefficient and not desirable in most GEMMs, owing to the slow progression of the disease. However, some of the new rapidly progressing prostate GEMMs, especially those marked with fluorescent molecules, might enable further study of CTCs and DTCs in GEMMs 246 . Some of the mouse prostate cancer marker orthologues that exist could be useful for detecting mouse CTCs and BM-DTCs, with the intent to characterize and study their sensitivity and specificity in an experimental model. Ultimately, mouse models have been invaluable tools to model prostate development and disease, but detecting human prostatespecific markers on prostate cancer cells in human blood or blood marrow has no substitute.
Using markers to detect rare cells Despite improvements in early detection and advances in treatment, some patients with prostate cancer continue to have poor outcomes, largely owing to bone metastasis. CTCs and BM-DTCs are the source of overt bone metastases; therefore, these rare cells can offer important clinical insights, as well as improved understanding of the biology underlying successful dissemination 12, 14, 247 . CTCs are a cell population that will probably be more clinically useful in real time than BM-DTCs, owing to easier sample access; however, BM-DTCs might be a more biologically important cell population because they have successfully disseminated. Detecting and accurately identifying BM-DTCs is difficult owing to their rarity and the lack of sensitive and specific protein markers. Putative CTCs can generally be found using epithelial markers in immunofluorescence assays, but BM-DTCs are more difficult to assess because of the complex cellular heterogeneity of the bone marrow relative to the blood, which includes autofluorescent cell types and proteins (such as large macrophages and collagen) and cells that can express certain epithelial markers (such as EpCAM) 248, 249 . Certain cancer-specific markers (such as MYC) might be expressed in rare cancer cells, but they are often also expressed in a variety of other cells in blood and bone marrow. Thus, we propose that using prostate-specific markers could improve the accurate detection of rare prostate cells in liquid biopsies.
New challenges have arisen with regard to the specificity of putative prostate-specific markers owing to the sensitivity requirement of rare cell assays (detection grossly apparent in the human prostate, which surrounds the urethra at the base of the bladder, but it is separated into zones for grading and staging purposes. b | Several lobes (the anterior lobe, which is immediately next to the seminal vesicles; and the dorsolateral and ventral lobes, which are anatomically similar to those of the human prostate and are at the base of the prostate) are present in the mouse prostate 230, 231 . Part a adapted from reF.
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, Springer Nature Limited.
www.nature.com/nrurol level of one single cancer cell in a field of millions of WBCs). Several prostate-specific markers are used to help differentiate prostate cancer tumours from other types of cancer, particularly in the metastatic setting. In rare cell assays, the use of RT-PCR and immunofluoresence (coupled with automated scanning microscopy) 31, 250 enables highly sensitive detection of RNA and protein, respectively. However, published reports about the specificity of these putative prostate-specific markers were not focused on rare cell detection but rather sectioned tissue and, therefore, were not aimed on confirming that every positively stained cell was indeed of prostatic origin. A protein that is considered sensitive and specific in a tissue-based assay might not be considered as such in a rare cell assay. For example, if a bone marrow liquid biopsy sample containing 10 million WBCs was to be stained for a putative cancer-specific marker, and only 0.01% of WBCs expressed that marker, approximately 1,000 WBCs would incorrectly be identified as a cancer cell using highly sensitive scanning techniques. Thus, putative prostate cancer markers require rigorous testing in known control and patient samples using rare cell-based assays, rather than tissue-based assays 251, 252 . RNA from formalin-fixed CTCs or cells obtained via fluorescence-activated cell sorting (FACS) or selection techniques and assessed using RT-PCR for finite gene panels is one promising methodology 35 . New technologies, such as multiplexed ion beam imaging coupled with mass cytometry to determine the expression of a panel of approximately 100 markers at one time could be extremely useful to ascertain sensitivity and specificity of markers in rare cells assays [253] [254] [255] . For immunofluorescence-based assays, the selection of the detection antibody is particularly important, as staining patterns and positivity can vary widely 256 . Polyclonal antibodies are generally more sensitive and have a higher probability of detection in a range of different conditions than the monoclonal antibodies, but they are generally less specific 257 . Many other factors can influence the staining of an antibody, such as tissue processing, fixation reagents and timing, antigen retrieval type and timing, microscope type, and automated scanning settings [258] [259] [260] . Proper training at each of these stages, as well as proper recording and communication of protocols, is of utmost importance during the process of identifying new markers for rare cell assays 261 . Even if an antibody has been rigorously tested, depending on the type of tissue and exact staining protocol involved, false positivity or negativity can still occur. For instance, NKX3.1 is present in the nucleus of prostate cells and can sensitively be called a true positive in the nucleus, but it can also stain in the cytoplasm of other tissues and, therefore, be incorrectly labelled as being positive for that marker 188 . Markers that only stain in the cytoplasm, such as PSA, might not be ideal markers for rare cell assays because diffuse false-positive cytoplasmic staining is occasionally seen simply owing to processing. Thus, combining markers that have different staining patterns using multiplex staining is preferable. For example, an ideal multiplex protocol might include a nuclear marker (such as HOXB13), cytoplasmic marker (such as PSA), and a marker with a unique staining pattern (such as prostein, which localizes to the Golgi apparatus) (Fig. 3) . Immunofluorescence can provide more information than other techniques, such as RT-PCR: RT-PCR is more sensitive in terms of its ability to detect small amounts of RNA, but this technique does not provide information about cellular heterogeneity in terms of which cells express which RNA 262 . Immunofluoresence can provide visual evidence of protein expression and in multiplex assays can provide expression information about multiple proteins in a single cell 263 . Given the fact that protein expression provides insight into function, immunofluoresence-based assays also have the advantage of improving understanding of the role of detected cells, enabling clinical application of protein expression to guide disease management 264 . In addition, single-cell picking techniques have improved, meaning genomic and proteomic analyses can now be performed at the single-cell level 28, [265] [266] [267] . Single-cell picking can provide increased confidence that putative CTCs and BM-DTCs are indeed cancer cells. This technology can also provide further information about the underlying molecular pathology of selected cancer cells that could potentially provide guidance as to treatment of the patient 268 . Each prostate marker has a varying degree of specificity to the prostate gland or prostate cancer. Some, like PSA, prostein, HOXB13, and KLK2, seem to be highly specific for prostate tissue, on the basis of tissuebased assays, whereas others, like AR, PSAP, PSCA, and PSMA are much less specific. In addition, some markers become aberrantly expressed in a variety of cancers, even if they were not expressed in the corresponding nonmalignant tissue. However, we postulate that a prostatespecific marker only needs to be specific for prostate cancer cells in that any other cells that are present in a liquid biopsy do not express the marker. These cells include blood and bone marrow cells such as all immune , whereby a marker of interest that is highly expressed in prostate cells but is also expressed in, for example, pancreatic cells would still be acceptable for use in a liquid biopsy.
The sensitivity of the detection marker is also extremely important to ensure that every prostate cancer cell that is present in a blood or bone marrow sample from a patient is identified. As CTCs and BM-DTCs are so rare, failing to detect only a few cells could have major clinical implications, meaning that every prostate cancer cell that enters the bloodstream and/or bone marrow would ideally express the detection marker. Unfortunately, information to this degree is severely lacking. Most reports have determined the sensitivity of prostate markers using IHC, and sensitivity is discussed in terms of the percentage of patient samples in which positive staining was observed. Instead, for rare cell assays, the number of prostate cancer cells that are detected with the marker out of a known total number of prostate cells present should be determined. Assessing clinical samples in this manner might not be possible, considering no perfectly sensitive marker exists to our knowledge that would provide the true number of cancer cells present in a sample. To overcome these obstacles, increasing the number of markers to enable identification of every cell would be helpful, as long as they are each highly specific. However, for some less common types of prostate cancer (such as neuroendocrine, small-cell, or carcinoid), the classic prostate markers like PSA and NKX3.1 will not be helpful 107 . An important concept to consider is that a marker does not need to be as sensitive or specific if it is not being used for detection purposes. Once the CTC or BM-DTC is detected by highly sensitive and specific markers, it does not matter whether a marker being used to study biological characteristics or to drive therapeutic decisions is also present on a blood or bone marrow cell not derived from prostate cancer. For example, AR is a relatively non-prostate-specific marker, as it is expressed in many other healthy tissues, including the bone marrow. Thus, we would not recommend using AR to detect or identify prostate cancer CTCs or BM-DTCs; however, the expression of full-length AR or a variant form (such as AR-V7) on prostate cancer cells identified with prostate-specific markers can aid clinical decisionmaking when treating metastatic prostate cancer 21, 23, 110 . This example illustrates the importance and applicability of using liquid biopsies and rare cell assays on liquid biopsy sampling as patient care can be directly affected.
Conclusions
This Review discusses the difficulties in accurately identifying rare prostate CTCs or BM-DTCs with the commonly used epithelial markers and the resulting need for prostate-specific biomarkers for the detection of these cells. Much has been done to identify and quantify CTCs in the blood of patients with cancer, but identifying BM-DTCs is less well studied. BM-DTCs are probably the most important CTCs as they are responsible for lethal bone metastases and, therefore, contain the biological characteristics required for successful dissemination. As rare cell assays need to be exceptionally sensitive, sensitive and specific markers are crucial for differentiating cancer cells from blood and bone marrow cells, but, unfortunately, little is known about candidate marker expression in prostate cancer cells at an individual cell level. Some markers, such as AR and PSAP, are too nonspecific to be used as individual markers of prostate cancer cells, whereas others, such as PSA, prostein, and HOXB13, have more promise as sensitive and specific markers. Multiple specific markers will probably have to be combined to increase overall sensitivity. The goal of future studies must be to consistently and reliably identify rare cancer cells using sensitive and specific markers. 
